Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children

NCT00988156 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT00988156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00988156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2007
Completion date
August 24, 2017
Enrollment
304 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

partial epilepsy in children and adolescents